Competing risk analysis after DLI: impact of donor source as a covariate
| Variables . | aGVHD . | cGVHD . | ||
|---|---|---|---|---|
| HR∗ (95% CI) . | P value . | HR∗ (95% CI) . | P value . | |
| Age at transplant | 0.99 (0.93-1.06) | .83 | 0.97 (0.90-1.06) | .53 |
| Transplant year | ||||
| 2005-2009 (reference) | ||||
| 2010-2015 | 1.21 (0.48-3.08) | .68 | 0.81 (0.24-2.72) | .74 |
| 2016-2021 | 1.57 (0.63-3.92) | .34 | 1.15 (0.35-3.75) | .82 |
| Diagnosis | ||||
| ALL (reference) | ||||
| AML | 2.12 (0.81-5.49) | .12 | 2.68 (0.74-9.79) | .14 |
| Other leukemias | 2.50 (0.77-8.12) | .13 | 2.10 (0.34-12.97) | .50 |
| Nonmalignant | 0.84 (0.24-3.03) | .80 | 0.46 (0.05-3.95) | .48 |
| Days from HCT to DLI | 0.98 (0.96-0.99) | <.001 | 0.99 (0.97-1.00) | .06 |
| CD3+ cell dose (first DLI) | 0.93 (0.84-1.03) | .17 | 1.03 (0.98-1.09) | .21 |
| Cell source | ||||
| PBSC (reference) | ||||
| BM | 0.41 (0.07-2.38) | .32 | 1.13 (0.10-12.90) | .92 |
| Variables . | aGVHD . | cGVHD . | ||
|---|---|---|---|---|
| HR∗ (95% CI) . | P value . | HR∗ (95% CI) . | P value . | |
| Age at transplant | 0.99 (0.93-1.06) | .83 | 0.97 (0.90-1.06) | .53 |
| Transplant year | ||||
| 2005-2009 (reference) | ||||
| 2010-2015 | 1.21 (0.48-3.08) | .68 | 0.81 (0.24-2.72) | .74 |
| 2016-2021 | 1.57 (0.63-3.92) | .34 | 1.15 (0.35-3.75) | .82 |
| Diagnosis | ||||
| ALL (reference) | ||||
| AML | 2.12 (0.81-5.49) | .12 | 2.68 (0.74-9.79) | .14 |
| Other leukemias | 2.50 (0.77-8.12) | .13 | 2.10 (0.34-12.97) | .50 |
| Nonmalignant | 0.84 (0.24-3.03) | .80 | 0.46 (0.05-3.95) | .48 |
| Days from HCT to DLI | 0.98 (0.96-0.99) | <.001 | 0.99 (0.97-1.00) | .06 |
| CD3+ cell dose (first DLI) | 0.93 (0.84-1.03) | .17 | 1.03 (0.98-1.09) | .21 |
| Cell source | ||||
| PBSC (reference) | ||||
| BM | 0.41 (0.07-2.38) | .32 | 1.13 (0.10-12.90) | .92 |
P values <.05 are in bold font.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; PBSC, peripheral blood stem cells.
Adjusted for transplant type.